Look out Gilead, AbbVie’s hep C combo comes with stellar data, 8-week regimen and a killer price
The FDA handed AbbVie an OK and a helpful label on Thursday for its new combo therapy for hepatitis C. And now they’re rolling it into an intensely competitive market with a lowball price for the first 8-week regimen that covers all the major genotypes of the disease.
In other words, look out Gilead.
The drug’s commercial name is Mavyret, a combination of pibrentasvir combined with Enanta’s glecaprevir. Starting with the standard 8-week course and then jumping to 12 and 16 weeks if necessary, researchers have tracked cure rates starting at 92% and rising to 100%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.